SCHEMBL3606398

SCHEMBL3606398

Cc1ccc(Cn2cc(NC(=O)c3ccc4c(c3)CCNC4)cn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
NAMPT P43490 3/20 0.48
RPS6KA2 Q15349 8/20 0.47
WNT1 P04628 1/20 0.47
GSK3B P49841 1/20 0.47
DYRK1A Q13627 1/20 0.47
CYP1A2 P05177 2/20 0.47
MAPT P10636 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
PLA2G1B P04054 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RPS6KA3 P51812 2/20 0.46
POLB P06746 1/20 0.46
F2 P00734 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602522 0.91 SMN1; SMN2 (0.60) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
SCHEMBL3608431 0.91 NAMPT (0.56) SMN1; SMN2NAMPTCYP1A2MAPTCYP2C9
SCHEMBL13504884 0.90 NAMPT (0.60) NAMPTRPS6KA2ALDH1A1RPS6KA3
SCHEMBL13504909 0.90 SMN1; SMN2 (0.52) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
SCHEMBL3608690 0.90 TAS2R8 (0.52) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
Hydrochloric Acid SCHEMBL3612494 0.90 NAMPT (0.59) NAMPTRPS6KA2ALDH1A1RPS6KA3
Hydrochloric Acid SCHEMBL3610939 0.89 SMN1; SMN2 (0.51) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
SCHEMBL3613929 0.89 SMN1; SMN2 (0.59) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
SCHEMBL3605849 0.88 NAMPT (0.49) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B
Hydrochloric Acid SCHEMBL3596683 0.88 SMN1; SMN2 (0.58) SMN1; SMN2NAMPTRPS6KA2WNT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US claimed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
WO-2008074824-A2 ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) SMITHKLINE BEECHAM CORPORATION (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041696-A1 Compounds CYP11B2, SCD, CYP3A5 SMN1; SMN2 618/4885NAMPT 869/4885RPS6KA2 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.